60 Degrees Pharmaceuticals Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Geoffrey Dow

Directeur général

US$125.6k

Rémunération totale

Pourcentage du salaire du PDG	100.0%
Durée du mandat du directeur général	2.4yrs
Propriété du PDG	3.4%
Durée moyenne d'occupation des postes de direction	1.6yrs
Durée moyenne du mandat des membres du conseil d'administration	1.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Geoffrey Dow a-t-elle évolué par rapport aux bénéfices de 60 Degrees Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$2m
Mar 31 2024	n/a	n/a	-US$853k
Dec 31 2023	US$126k	US$126k	-US$4m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$55k	US$55k	-US$6m
Sep 30 2022	n/a	n/a	-US$6m
Dec 31 2021	US$520k	US$520k	-US$4m
Dec 31 2020	US$283k	US$283k	-US$3m

Rémunération vs marché: La rémunération totale de Geoffrey ($USD 125.56K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 650.80K ).

Rémunération et revenus: La rémunération de Geoffrey a augmenté alors que l'entreprise n'est pas rentable.

PDG

Geoffrey Dow (50 yo)

2.4yrs

Titularisation

US$125,555

Compensation

Dr. Geoffrey Stuart Dow serves as President, Chief Executive Officer and Director at 60 Degrees Pharmaceuticals, Inc. since June 1, 2022. Dr. Dow is Chairman, President and CEO of 60° Pharmaceuticals, LLC....

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Geoffrey Dow	Chairman	no data	US$125.56k	3.41% $ 55.5k
Tyrone Miller	CFO & Treasurer	1.8yrs	US$135.63k	0.79% $ 12.9k
Bryan Smith	Chief Medical Officer	8.8yrs	pas de données	pas de données
Kristen Landon	Chief Commercial Officer	less than a year	pas de données	pas de données
Jennifer Herz	Director	1.3yrs	pas de données	pas de données

1.6yrs

Durée moyenne de l'emploi

53.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de SXTP n'est pas considérée comme expérimentée (ancienneté moyenne 1.6 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Geoffrey Dow	Chairman	2.4yrs	US$125.56k	3.41% $ 55.5k
Charles Allen	Independent Director	1.3yrs	US$121.83k	0.063% $ 1.0k
Stephen Toovey	Independent Director	1.3yrs	US$120.33k	0.063% $ 1.0k
Paul Field	Independent Director	1.3yrs	US$120.33k	0.063% $ 1.0k
Cheryl Xu	Director	1.3yrs	US$117.83k	2.21% $ 35.9k

1.3yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la SXTP n'est pas considéré comme expérimenté ( 1.3 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

60 Degrees Pharmaceuticals Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

60 Degrees Pharmaceuticals Inc. Announces ARAKODA Promotional Pilot in Advance of Expanded U.S. Launch

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$4.68 loss

60 Degrees Pharmaceuticals, Inc. Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals Announces 1:12 Reverse Stock Split to Bring the Company into Compliance with the Nasdaq's $1.00 Minimum Bid Price Requirement for Maintaining its Nasdaq Listing

New major risk - Share price stability

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.253603 million.

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.253603 million.

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia Microti Despite Prior Treatment

60 Degrees Pharmaceuticals, Inc. Announces First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center

60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients

Consensus revenue estimates fall by 13%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2024

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

High number of new and inexperienced directors

60 Degrees Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $2.4001 million.

60 Degrees Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $2.400101 million.

60 Degrees Pharmaceuticals, Inc. Plans Pivotal Babesiosis Study with Tafenoquine

60 Degrees Pharmaceuticals, Inc. Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

60 Degrees Pharmaceuticals, Inc. announced delayed 10-Q filing

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

60 Degrees Pharmaceuticals, Inc.'s Subsidiary 60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Second quarter 2023 earnings released

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

60 Degrees Pharmaceuticals, Inc. Registers ACLR8-LR

New major risk - Market cap size

High number of new and inexperienced directors

60 Degrees Pharmaceuticals Receives Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

60 Degrees Pharmaceuticals, Inc. has completed an IPO in the amount of $7.500004 million.

60 Degrees Pharmaceuticals, Inc. has completed an IPO in the amount of $7.500004 million.

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen